Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sr-13668. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.52 |
| ▸ | TUBB | P07437 | 2/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sr-13668 SCHEMBL30173443 | 1.00 | KDM4E (0.64) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| Sr-13668 SCHEMBL29381258 | 1.00 | KDM4E (0.64) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12642105 | 0.95 | KDM4E (0.58) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL18705463 | 0.94 | KDM4E (0.57) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3199051 | 0.90 | KDM4E (0.64) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3187981 | 0.88 | HCRTR1 (0.70) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1120941 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3197990 | 0.86 | KDM4E (0.67) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12968290 | 0.86 | KDM4E (0.67) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13535329 | 0.86 | KDM4E (0.60) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| US-20200179337-A1 | MEANS FOR TREATING SEXUALLY TRANSMITTED INFECTIONS | AKTSIONERNOE OBSCHESTVO "VELES FARMA" (RU) | 2020-06-11 | — | — | US | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-2694057-B1 | LIPOXYGENASE INHIBITORS | STANFORD RES INST INT (US) | 2019-06-05 | — | — | EP | claimed |
| US-9663462-B2 | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles | BIORESPONSE, L.L.C. (US) | 2017-05-30 | — | — | US | claimed |
| US-9353058-B2 | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles | BIORESPONSE, L.L.C. (US) | 2016-05-31 | — | — | US | claimed |
| US-20160101083-A1 | ANTI-PARASITIC METHODS AND COMPOSITIONS UTILIZING DIINDOLYLMETHANE-RELATED INDOLES | BIORESPONSE, L.L.C. (US) | 2016-04-14 | — | — | US | claimed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | claimed |
| US-20140037577-A1 | ANTI-PARASITIC METHODS AND COMPOSITIONS UTILIZING DIINDOLYLMETHANE-RELATED INDOLES | BIORESPONSE, L.L.C. | 2014-02-06 | — | — | US | claimed |
| EP-1865929-A2 | DIINDOLYLMETHANE-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PROMOTING ORAL MUCOSAL AND BONE HEALTH | Bioresponse, L.L.C. (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1838303-A2 | USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS ASSOCIATES CONDITIONS | Bioresponse LLC (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060264497-A1 | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | BIORESPONSE, L.L.C. | 2006-11-23 | — | — | US | claimed |
| WO-2006105196-A2 | DIINDOLYLMETHANE-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PROMOTING ORAL MUCOSAL AND BONE HEALTH | BIORESPONSE, L.L.C. (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006083458-A2 | USE OF DIINDOLYLMETHANE-RELATED INDOLES FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS ASSOCIATES CONDITIONS | BIORESPONSE LLC (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060111423-A1 | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease | BIORESPONSE, L.L.C. | 2006-05-25 | — | — | US | claimed |
| WO-2006047716-A2 | USE OF DIINDOLYLMETHANE-RELATED INDOLES AND GROWTH FACTOR RECEPTOR INHIBITORS FOR THE TREATMENT OF HUMAN CYTOMEGALOVIRUS ASSOCIATED DISEASE | BIORESPONSE LLC (US) | 2006-05-04 | — | — | WO | claimed |
| US-20050267193-A1 | Diindolylmethane formulations for the treatment of leiomyomas | BIORESPONSE, LLC | 2005-12-01 | — | — | US | claimed |
| WO-2005107747-A2 | DIINDOLYMETHANE FORMULATIONS FOR THE TREATMENT OF LEIOMYOMAS | BIORESPONSE, LLC (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050063903-A1 | cruciferous-related indole particulary diindolylmethanes, zinc/iron chelator, and optionally one or more of a zinc-binding histone deacetylase inhibitor, gallium or an EGFR antagonist, are administered simultaneously | BIORESPONSE L.L.C. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101083-A1 | ANTI-PARASITIC METHODS AND COMPOSITIONS UTILIZING DIINDOLYLMETHANE-RELATED INDOLES | CASP3, IDO1, INMT | KDM4E 3429/4885ALDH1A1 4436/4885MAPT 4079/4885 |
| US-20140037577-A1 | ANTI-PARASITIC METHODS AND COMPOSITIONS UTILIZING DIINDOLYLMETHANE-RELATED INDOLES | CASP3, IDO1, INMT | KDM4E 3429/4885ALDH1A1 4436/4885MAPT 4079/4885 |
| US-20060264497-A1 | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | HPGDS, IDO1, IDO2 | KDM4E 1103/4885ALDH1A1 2982/4885MAPT 4397/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | KDM4E 1965/4885ALDH1A1 805/4885MAPT 2470/4885 |
| US-20060111423-A1 | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease | EGFR, IGF1R, MIF | KDM4E 2458/4885ALDH1A1 1897/4885MAPT 3004/4885 |
| US-20050267193-A1 | Diindolylmethane formulations for the treatment of leiomyomas | IDO1, IDO2, EDNRA | KDM4E 1025/4885ALDH1A1 2672/4885MAPT 4268/4885 |
| US-20050063903-A1 | cruciferous-related indole particulary diindolylmethanes, zinc/iron chelator, and optionally one or more of a zinc-binding histone deacetylase inhibitor, gallium or an EGFR antagonist, are administered simultaneously | EZH2, EGFR, ZKSCAN2 | KDM4E 435/4885ALDH1A1 4363/4885MAPT 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.